Empagliflozin use feasible for HFpEF patients whether or not they are taking diuretics: JAMA Medha Baranwal29 May 2023 5:45 AM GMTUSA: Empagliflozin treatment in patients with heart failure and preserved ejection fraction (HFpEF) is similar regardless of diuretic dose or use; and...
Empagliflozin reduces heart failure events across spectrum of CKD: Analysis of EMPEROR trials Medha Baranwal11 May 2023 5:15 AM GMTUSA: Empagliflozin (Jardiance) consistently reduced heart failure (HF) events across the spectrum of chronic kidney disease (CKD), according to...
Eli Lilly-Boehringer's Jardiance for children with type 2 diabetes accepted by USFDA Ruchika Sharma10 March 2023 6:53 AM GMTIndianapolis: Boehringer Ingelheim and Eli Lilly and Company have announced that the U.S. Food and Drug Administration (FDA) has accepted a...
Empagliflozin tied to meaningful reduction of HbA1c compared to linagliptin in young diabetes patients: Lancet Jacinthlyn Sylvia9 March 2023 5:45 AM GMTA new study published in The Lancet Diabetes & Endocrinology suggests that linagliptin did not reduce HbA1c in a clinically meaningful way,...
SGLT2 inhibitor empagliflozin could be new treatment option for children with type 2 diabetes: Lancet Dr. Kamal Kant Kohli4 March 2023 5:30 AM GMTUSA: Empagliflozin could be a new treatment option for children and adolescents with type 2 diabetes, findings from a phase 3 clinical trial have...
Medical Bulletin 25/February/2023 Isra Zaman25 Feb 2023 9:15 AM GMTHere are the top medical news for the day: Oral empagliflozin provided safe glycemic control in children with type 2 diabetes: Phase 3 trial...
Oral empagliflozin provided safe glycemic control in children with type 2 diabetes: Phase 3 trial findings Isra Zaman25 Feb 2023 3:30 AM GMTResearchers led by pediatric endocrinologists at Joslin Diabetes Center recently completed a phase 3 clinical trial that assessed the efficacy and...
Empagliflozin promising in hyponatremia induced by Chronic Syndrome of Inappropriate Antidiuresis Dr Kartikeya Kohli10 Feb 2023 6:00 AM GMTSwitzerland: According to clinical research on acid-base and electrolyte disorders, the sodium-glucose cotransporter 2 (SGLT2) inhibitor...
USFDA accepts supplemental New Drug Application for Jardiance for adults with chronic kidney disease: Eli Lilly Ruchika Sharma22 Jan 2023 6:30 AM GMTIndianapolis: The U.S. Food and Drug Administration (USFDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin)...
Torrent Pharma collaborates with Boehringer Ingelheim India to co-market its anti-diabetic drug, its fixed dose combinations in India Ruchika Sharma14 Dec 2022 11:20 AM GMTAhmedabad: Torrent Pharmaceuticals Ltd has entered into a strategic alliance with Boehringer Ingelheim India Private Limited to co-market Cospiaq...
Empagliflozin improves outcomes in HF with preserved EF irrespective of BP: the EMPEROR-Preserved trial Medha Baranwal13 Dec 2022 5:00 AM GMTGermany: Empagliflozin reduces the risk of heart failure (HF) hospitalization or cardiovascular (CV) death in HRpEF (heart failure and preserved...
Empagliflozin as add-on therapy improves quality of life in diabetes patients Medha Baranwal28 Nov 2022 4:45 AM GMTPunjab: Empagliflozin can be recommended as an add-on medication in type 2 diabetes (T2D) patients with hypertension with regards to improving their...
